Structural Remission of Myxomatous Mitral Regurgitation and Prevention of Congestive Heart Failure Through the Pharmacology of Evolution: The Neuro-Executive Paradigm

biomechanical prelude to Congestive Heart Failure (CHF). The standard allopathic approach resigns itself to symptomatic containment via beta-blockers and angiotensin II receptor blockers (ARBs), assuming the irreversibility of tissue damage. This paper demonstrates the superiority of a radical psychosomatic intervention—based on the assumption of executive autonomy—to reverse the condition. Case Description: A male patient diagnosed at age 18 with mild mitral valve prolapse and regurgitation, progressing to moderate by age 25. The clinical picture presented concentric hypertrophy and an imminent risk of diastolic dysfunction. The intervention consisted of applying the "Pharmacology of Evolution": a total redesign of limiting beliefs, assuming territorial control, and adopting a relentless CEO mindset. Results: The post-intervention echocardiographic study revealed the total absence of mitral regurgitation and the complete reversal of ventricular hypertrophy. The mindset shift suppressed the allostatic load, operating physiologically with greater precision than a dual regimen of beta-blockers and ARBs. Conclusion: Cognitive empowerment and executive proactivity act as direct hemodynamic modulators, eradicating the valvular symptom, reversing tissue degeneration, and rewriting the prevention protocols for Congestive Heart Failure.